Commerzbank Aktiengesellschaft FI Increases Position in Cencora, Inc. (NYSE:COR)

Commerzbank Aktiengesellschaft FI increased its stake in Cencora, Inc. (NYSE:COR) by 23.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,192 shares of the company’s stock after acquiring an additional 225 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Cencora were worth $268,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Cencora by 3.8% during the third quarter. State Street Corp now owns 8,045,896 shares of the company’s stock valued at $1,810,970,000 after buying an additional 291,867 shares during the period. Wellington Management Group LLP boosted its position in Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock valued at $1,168,927,000 after buying an additional 338,452 shares during the period. Geode Capital Management LLC boosted its position in Cencora by 4.7% during the third quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company’s stock valued at $941,183,000 after buying an additional 189,054 shares during the period. Pacer Advisors Inc. boosted its position in Cencora by 6.7% during the fourth quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company’s stock valued at $495,249,000 after buying an additional 138,868 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company’s stock valued at $368,771,000 after buying an additional 292,600 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 4,970 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,648 shares of company stock worth $2,862,342 over the last three months. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. StockNews.com lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Stock Performance

Shares of NYSE:COR opened at $251.40 on Thursday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a market cap of $48.75 billion, a price-to-earnings ratio of 35.76, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The company has a 50-day moving average price of $243.25 and a 200-day moving average price of $238.18. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.